Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar;13(1):55-67.
doi: 10.28092/j.issn.2095-3941.2016.0002.

Genetic Evaluation and Testing for Hereditary Forms of Cancer in the Era of Next-Generation Sequencing

Affiliations
Free PMC article

Genetic Evaluation and Testing for Hereditary Forms of Cancer in the Era of Next-Generation Sequencing

Christine Stanislaw et al. Cancer Biol Med. .
Free PMC article

Abstract

The introduction of next-generation sequencing (NGS) technology in testing for hereditary cancer susceptibility allows testing of multiple cancer susceptibility genes simultaneously. While there are many potential benefits to utilizing this technology in the hereditary cancer clinic, including efficiency of time and cost, there are also important limitations that must be considered. The best panel for the given clinical situation should be selected to minimize the number of variants of unknown significance. The inclusion in panels of low penetrance or newly identified genes without specific actionability can be problematic for interpretation. Genetic counselors are an essential part of the hereditary cancer risk assessment team, helping the medical team select the most appropriate test and interpret the often complex results. Genetic counselors obtain an extended family history, counsel patients on the available tests and the potential implications of results for themselves and their family members (pre-test counseling), explain to patients the implications of the test results (post-test counseling), and assist in testing family members at risk.

Keywords: Genetic counseling; genetic testing; high-throughput nucleotide sequencing; informed consent; neoplastic syndromes, hereditary.

Similar articles

See all similar articles

Cited by 13 articles

See all "Cited by" articles

References

    1. Lu KH, Wood ME, Daniels M, Burke C, Ford J, Kauff ND, et al. American society of clinical oncology expert statement: collection and use of a cancer family history for oncology providers. J Clin Oncol. 2014;32: 833–40. doi: 10.1200/JCO.2013.50.9257. - DOI - PMC - PubMed
    1. Hall MJ, Forman AD, Pilarski R, Wiesner G, Giri VN. Gene panel testing for inherited cancer risk. J Natl Compr Canc Netw. 2014;12: 1339–46. - PubMed
    1. Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K, American Society of Clinical Oncology. American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2010;28: 893–901. doi: 10.1200/JCO.2009.27.0660. - DOI - PubMed
    1. Fecteau H, Vogel KJ, Hanson K, Morrill-Cornelius S. The evolution of cancer risk assessment in the era of next-generation sequencing. J Genet Couns. 2014;23: 633–9. doi: 10.1007/s10897-014-9714-7. - DOI - PubMed
    1. Slavin TP, Niell-Swiller M, Solomon I, Nehoray B, Rybak C1, Blazer KR, et al. Clinical application of multigene panels: challenges of Next-Generation counseling and cancer risk management. Front Oncol. 2015;5: 208. - PMC - PubMed

LinkOut - more resources

Feedback